Helsinn Healthcare SA Reaches Settlement Agreement Regarding Patent Dispute On ALOXI®
LUGANO, Switzerland, January 12, 2015 /PRNewswire/ --
Helsinn Healthcare SA announces that it has entered into a settlement agreement with Sandoz Inc. to resolve their patent litigations relating to Helsinn Healthcare's Aloxi® (palonosetron HCl injection) in the US, where it is currently distributed by Helsinn Healthcare's marketing partner, Eisai Inc.
As a result of the settlement, Sandoz Inc. will be permitted to market a generic version of Aloxi® in the United States on September 30, 2018 or earlier under certain circumstances. The terms of the settlement agreement are otherwise confidential.
About the Helsinn Group
Helsinn Healthcare SA is a company belonging to the Helsinn Group, a family run, privately owned pharmaceutical group focused on building quality cancer care with a large portfolio of products. Founded in 1976 with headquarters in Lugano, Switzerland, Helsinn also has operating subsidiaries in Ireland, the United States and a representative office in China. Helsinn's business model is focused on the licensing of pharmaceuticals, medical devices and nutritional supplement products in the therapeutic area of cancer care. Helsinn is committed to advancing quality patient care through the development and commercialization of cancer supportive care treatments to benefit both patients and caregivers. Helsinn focuses R&D investments and resources on enhancing cancer supportive care, a still underserved yet important therapeutic area.
Helsinn Group in-licenses early-to-late stage new chemical entities, completing their development by performing preclinical and clinical studies and associated manufacturing activities. Helsinn then prepares necessary regulatory filings in order to achieve marketing approvals worldwide. Helsinn's products are out-licensed to its global network of marketing and commercial partners that have been selected for their local market knowledge. Helsinn supports these partners by providing a full range of product and scientific management services, including commercial, regulatory, and medical marketing advice. In March 2013, Helsinn established a new commercial organization within its subsidiary, Helsinn Therapeutics (U.S.), Inc., in order to conduct direct sales and marketing activities within the U.S. market. Helsinn's products are manufactured according to the highest quality, safety, and environmental standards at Helsinn's GMP facilities in Switzerland and Ireland from where they are then supplied worldwide to customers.
For more information please contact:
Helsinn Group
Paola Bonvicini
Head of Communication & Press Office
PH +41-91-985-21-21
info-hhc@helsinn.com
For media / external enquiries
Mary-Jane Elliott / Jessica Hodgson / Matthew Neal / Laura Thornton
Tel: +44(0)203-709-5700
Helsinn@consilium-comms.com
Help employers find you! Check out all the jobs and post your resume.
Helsinn Healthcare SA announces that it has entered into a settlement agreement with Sandoz Inc. to resolve their patent litigations relating to Helsinn Healthcare's Aloxi® (palonosetron HCl injection) in the US, where it is currently distributed by Helsinn Healthcare's marketing partner, Eisai Inc.
As a result of the settlement, Sandoz Inc. will be permitted to market a generic version of Aloxi® in the United States on September 30, 2018 or earlier under certain circumstances. The terms of the settlement agreement are otherwise confidential.
About the Helsinn Group
Helsinn Healthcare SA is a company belonging to the Helsinn Group, a family run, privately owned pharmaceutical group focused on building quality cancer care with a large portfolio of products. Founded in 1976 with headquarters in Lugano, Switzerland, Helsinn also has operating subsidiaries in Ireland, the United States and a representative office in China. Helsinn's business model is focused on the licensing of pharmaceuticals, medical devices and nutritional supplement products in the therapeutic area of cancer care. Helsinn is committed to advancing quality patient care through the development and commercialization of cancer supportive care treatments to benefit both patients and caregivers. Helsinn focuses R&D investments and resources on enhancing cancer supportive care, a still underserved yet important therapeutic area.
Helsinn Group in-licenses early-to-late stage new chemical entities, completing their development by performing preclinical and clinical studies and associated manufacturing activities. Helsinn then prepares necessary regulatory filings in order to achieve marketing approvals worldwide. Helsinn's products are out-licensed to its global network of marketing and commercial partners that have been selected for their local market knowledge. Helsinn supports these partners by providing a full range of product and scientific management services, including commercial, regulatory, and medical marketing advice. In March 2013, Helsinn established a new commercial organization within its subsidiary, Helsinn Therapeutics (U.S.), Inc., in order to conduct direct sales and marketing activities within the U.S. market. Helsinn's products are manufactured according to the highest quality, safety, and environmental standards at Helsinn's GMP facilities in Switzerland and Ireland from where they are then supplied worldwide to customers.
For more information please contact:
Helsinn Group
Paola Bonvicini
Head of Communication & Press Office
PH +41-91-985-21-21
info-hhc@helsinn.com
For media / external enquiries
Mary-Jane Elliott / Jessica Hodgson / Matthew Neal / Laura Thornton
Tel: +44(0)203-709-5700
Helsinn@consilium-comms.com
Help employers find you! Check out all the jobs and post your resume.